PTSD? OGD
`ages inc use muah BHaTaNT. ONS GAT
`LS, Salva ane Telemark Oiffos U8. OERARTMENT OF COMMERCE
`Linder the Papanwurks Recurtiun Actaf T3R5, ne peroura are Teguted fe rogpard io. a colsctan ev intamnetion untass 8 displays 9 valid OMEcuriea/ number,
`
`SUBSTITUTESTATEMENT
`
`Groumataroas aenmiting aacutios of this aubatiitte stationed
`[] trventor ts daenased,
`[}inventor is andar legal Inowpactty,
`[| venter cannot be found or naaehed alker dtlgent alfert, ar
`inemntor has natiatadt by aecute the aath or dacigration uneler 37 CAR 1.03.
`
`Shans. aang foind inventors, pleasecheckthe aggronrists box helen
`An appination datesheet under df GPR 178 (PTONARAH4 or emuivaiont) naming the antive mantive enilly has bean
`orfa currently submitted
`oe
`| An anglastion date sheaf under 37 CRRULIPTOUAIANS or aqubadent) has not bean adimitied. Thus, s Subatiuts
`Sinlament Gunglemenial Siwet (PFTOMAIAN f or equivalent} saning the anilInvertiwantliy and preasding inventor
`information & aiushwel, Gas 37 GFR Laeihh
`
`WARNING:
`fPellionsniagmicantis cautlaned ip avold audmiting pansone! iNarmatianik documents HedIn a patent anolowign that may
`tountibasdie to Stanly theft. Rorsanal ifomiation auchan scala! somey nunthers, bank acosuntnumbers, of orsdlt card rueribaes
`tfoiwer than o chiwek or oredll cant suihevinaiion fon PTOMSSS aubotiied for payment purses) le neers aquined by the USPTO
`fe Suppor8 pation OFsn apolication. Hthis typeaf penmonel infortatiie: is Inchated in dooney submited (6fhe USPTS,
`cara id conetierreclantinn HeeaapdaakmahatecichinObsnets berpilcehe So the
`
`
`2828 Dupont Drive-T2-7H whe i deeaaned,
`
`"T7eeA/SPRA”SECRETARS
`
`Ay pyak ~AineSPVGetal ¢AAS
`
`CecatingAddressfanlesspmesedt isansopteationdads Sent STORMANSarssanaiene :
`
`: reusedefiigorfloroFhasretisedtoexoculateothordeannur3?CFR 1.5.
`Pageofl
`
`inoapectintedl,
`
`gar
`
`.
`
`TEVA - EXHIBIT 1004 (PART 5 OF 5)
`
`0784
`
`0784
`
`TEVA - EXHIBIT 1004 (PART 5 OF 5)
`
`

`

`Frivany Act Statemant
`
`The Bivecy Jot of (8740. RTS) poquinss Sat yoube vem cartels iiemation by connantion
`with your eudrmiasion of tte etlached fim felated fo a patent anollogiion or patent. Accordingly,
`punkient §o Gre nequiremenie of See Ant, plneve be achtued Gab (1) the general authority for the
`exifinction af Sitsinformation b&b BS 6.0. ANE(2) Aanishieg oftes infomation sadiiied! ls woketanc
`ant (3)the pringisal purpose far which the information fe ined by fhe L.8. Patent and Trademark
`SNfiog ie to prooges andi examine your guiriesion ralatec! toa patent epplination or pehent. Hf youde
`fat flenishthe sequesied iibemagon, tee WS. Salant and Trademark Office migy sot be ablefs
`SOS Bader aaeiins aur ahenisainn, whinkmay nesue by derivation of gracaedtinga or
`abandonment of ihe analinaiion ar expiration of the patent
`
`The Infoemiavion grevkied hy you in this ern ad be euhiectfo the fling muting usa:
`
`%
`
`a
`
`The infomation on Gis ferns wil be feated! conlkientially to the extent alenwed unxler the
`Franco of nfarmalionAct (6 US... S88)andthePrivacy Acthi8 ULS.6 Atiial, Recordsfom
`“his Sytemof pcos mey be ditclngad hy thy Dainarimant at Juatine fo determine whether
`digcinaure of Sias asmored’s bk naguirad by the Fnsestant of Inormegias Bet
`&mead fom Gas eystenof pacords maybs ditsinwed, as a musing use, is dhe course of
`preaanthig evidence 8) A aku, magisineie, or ediminieivative fitunal, Including dleslonutes to
`oRsosing Souneelif the cou of selieent pyandiatons.
`A raased in this syatemof recerels maybe dlockoged, as 3 sasine wis, ss Marnier of
`GOORRENS submiiing « raguast imeohing an inciiduad, fo whoo the moon serisine, whan Sie
`indivilual has raquesiod aaaistenos Gorn fey Member with reapect to the auiect matter of the
`renord,
`A Rioard Be ihe Syatem of renaeeis mayfe dieciisad, ms a maine uae, ig caniectorof fhe
`
`Agancyancy Raving need forthe information in orderto pastor @ contract Recipfantsof
`
`information shad! be peated fo oorinly wilh they nacudromentsof the Privy Act of 1074, ax
`armaniiad, piven bs 8 UGG, Sete,
`A recoed relatedtoan interantional Apolcationfled uncer the Patent CGongeration Traaty in
`this ayater of nagords may be dissiosad, as 4fautins ues, 9 the intomaiongy Biumeng of the
`Woris Infalleciual Property Ceganination, purguant © Sie Patatt Gonearsiion Traake
`A Sasere! 8h Nts ayehort of renoris may be discioeed, a6 9 muting uae, bs anether Geleral
`agenoy for purposes of Netiene Saoutlty mk (89 U8. Het} wel for madiaypussuant io
`the Storms SramyAct {s2uUS.35. Naish.
`A sround from fas aysien of naouris may be diecioset, ae a ooutine ase, 13 the dadinishater,
`Genel Genviosg, or histor designee, ducing at Inapaction of mconie conducied fy GSA ay
`part affiat Sgancy’s PnONsiniity to rocemmand inorwanents in necurds management
`Sractnes and proawams, under authoriof 44 US. 2804 and S06, Such eliesiowire chal
`ba mace in mooonianes withthe GRAroguiasios governing napaction of rancedsfoc this
`puntos, and any ogher rlevant { 1a, GSA or Gomynenss) directing, Such deciieure shal rx
`be cael fo eke cstensinations about Iiduais,
`& secord fom vs sextaofraounds mayhes cleciased’, ag @ cusine uae, is the Gulille aker
`ether publinelion of the agnlication parsuent tc BS WSO, 12200) or aauanee of w patent
`pusstannt io OSOLS. 154, Bustier 0 seemed may ba disclouse, aubiset io doe findations of AF
`GFR 1.44, as A rouine as, 8 the public # the moan! wae fied in an angliontin which
`baneme abandoned oris whinh the proceadiigs seve feminatad and which apolination is
`asfienoneed by aiher9 puivighed apniicstion, anapolinetionopenfy suits Ingeection or an
`insuerd petant.
`A ronund fraen this gyshne af saesirels wuty he dincinand, ae & routine use, toe Federal, Siete,
`or fosal low enforsement ageney, Whe USPTObecomes avers af a Welaiion af aatundal
`wWelntion of lew ar nagudation,
`
`0785
`
`0785
`
`

`

`Doc Code: TRACK1.REG
`Dacument Description: TrackGne Request
`
`PTOVAIA/424 (03-14)
`
`CERTIFICATION AND REQUEST FOR PRIORITIZED EXAMINATION
`UNDER 37 CFR 1.102(e) (Page 1 of 1)
`
`g
`
`First Named
`Inventor:
`Tithe of
`invention:
`
`Nonpravisional Application Number (if
`g known):
`Andrew Acheampong
`| METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`APPLICANT HEREBY CERTIFIES THE FOLLOWING AND REQUESTS PRIORITIZED EXAMINATION FOR
`THE ABOVE-IDENTIFIED APPLICATION.
`
`1. The processing fee set forih in 37 CFR 1.170}(4}, the prioritized examination fee set forth in
`37 CFR 1.1/{c}, and if not already paid, the publication fee set forth in 37 CFR 1.18(c) have
`been filed with the request. The basic filing fee, search fee, and examination fee are filed with
`the request or have been already been paid.
`| undersiand that any required excess claims fees
`or application size fee must be paid for the application.
`
`funderstand that the application may not contain, or be amended to contain, more than four
`independent claims, more than thirty total claims, or any multiple dependent claims.
`
`3. The applicable box is checked below:
`
`Original Anolication (Track One} - Prioritized Examination under § 1.102(e}1}
`
`i.
`
`(a) The application is an original nonprovisional ulility application fled under 35 U.S.C. 111(a).
`This certification and request is being filed with the ullity application via EFS-Web.
`OR
`(b} The application is an original nonprovisional plant application filed under 35 U.S.C. 1114}.
`This certification and request is being filed with the plant application in paper.
`
`An executed inventor's oath or declaration under 37 CFR 1.63 or 37 CFR 1.64 for each
`inventor, or the application data sheet meeting the conditions specified in 37 CFR 1.530)(3)) is
`filed with the application.
`
`|
`
`|| Request for Continued Examination - Priocritized Examination under § 1.102/e}{2)}
`
`March 21, 2014
`(Practitioner
`=
`68681
`
`| Registration Number
`
`, *Total of
`
`A request for continued examination has been filed with, or prior to, this form.
`ifthe application is a utiity application, this certification and request is being fled via EFS-Web.
`iii. The application is an original nonprovisional ulllity application filed under 35 U.S.C. 111(a}, oris
`a national stage entry under 35 U.S.C. 371.
`iv. This certification and request is being fled prior to the mailing of a first Office action responsive
`fo the request for continued examination.
`Neo prior request for continued examination has been granted prioritized examination status
`under 37 CFR 1.102(e2).
`
`scrstue!t-aura L. Wine/
`|
`JNeme Laura L. Wine
`
`(Print/Typed}
`
`§
`
`This form rnust be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(a) for signature requirements and certifications.
`| Note:
`§ Submit multiole forms if more than one signature is required.*
`4
`forms are submitted.
`
`|
`
`0786
`
`0786
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (PL. 93-579) requires that you be given certain information in connection with your
`submission of the atlached form related to a patent application or patent. Accordingly, pursuant to the requirements of
`the Act, please be advised that: (1} the general authorily for the collection of this information is 35 U.S.C. 2(b\M2); (2)
`furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information Is used by the
`U.S. Patent and Trademark Office is to process and/or examine your submission related to a petent application ar
`patent. H you do not furnish the requested information, the U.S. Patent and Tradamark Office may not be able to
`process and/or examine your submission, which may resullin termination of proceedings or abandonment of the
`application or expiration of the patent,
`
`The information provided by you in this form will be sublect fo the following routine uses:
`
`4,
`
`cn
`
`The information on this form will be treated conficentially to the extent allowed under the Freedomof
`information Act (6 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may
`be disclased to the Department of Justice to determine whether disclosure of these records is required by the
`Freedom of Information Act.
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or aciministrative tribunal, including cisclasures to oppasing counsel in the course of
`settlement negotiations.
`A record in this system of records may be disclased, as a routine use, to a Member of Congress submitting a
`request involving an individual, to wham the record pertains, when the individual has requested assistance from
`the Member with respect to the subject matter of the record.
`Arecord in this system of records may be disclosed, as a routine use, to a contractor of the Agency having
`need for ine Information in order to perform a contract. Recipients of information shall be required to comply
`with the requirements of the Privacy Act of 1974, as amended, pursuant fo 5 U.S.C. 582a(m}.
`A record related to an International Application filed uncer the Patent Cooperation Treaty in this system of
`records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another federal agencyfor gurposes
`of National Securify review (25 ULS.C. 184) and for review pursuant to the Atomic Energy Act (42 U.S.C.
`248(c).
`A record fromthis system of records may be disclosed, as a routine use, to the Administrator, Genera
`Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency’s
`responsibility to recommend improvements in records management cractices and programs, uncer authority of
`44 U.S.C. 2904 and 2908. Such disclosure shall be made in accordance with the GSA regulations governing
`inspection of records for this purpose, and any other relevant (.¢6., GSA or Commerce) directive. Such
`disclosure shall not be used ts make determinations about individuals.
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance of a patent oursuant io 35 U.S.C. 154. Further, a
`racord may be disclosed, subject tc the limitations of 37 CFR 1.14, as a routine use, to ihe public if the record
`was filed in an application which became abandoned or in which the proceedings were terminated and which
`application is referenced by either a published application, an application anen to public inspection or an issued
`patent.
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`anforcement agency, if the USPTO becomes aware of a viclation or potential violation of law or requiation.
`
`0787
`
`0787
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`—
`
`document maybe printed and included in a paper filed application.
`
`Title of Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`The application data sheetis part of the provisional or nonprovisional application for whichit is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`
`Secrecy Order 37 CFR 5.2
`3/7 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`0 Portionsorall of the application associated with this Application Data Sheet mayfall under a Secrecy Order pursuantto
`
`Inventor Information:
`
`Inventor
`Legal Name
`
`1
`
`Residence Information (Select One) @ US Residency
`
`©) NonUS Residency
`
`(©) Active US Military Service
`
`Mailing Addressof Inventor:
`
`Address 2
`
`2
`Inventor
`Legal Name
`Family Name
`Prefix)GivenName Middle Name
`a
`Residence Information (Select One) @ US Residency
`(©) NonUS Residency
`(©) Active US Military Service
`
`() Active US Military Service
`
`Mailing Addressof Inventor:
`
`3726 Las Vegas Blvd., S Unit 3303 W
`
`Address1
`
`Address 2
`
`3
`Inventor
`Legal Name
`
`FE0
`Residence Information (Select One)
`(@) US Residency
`©) NonUS Residency
`
`EFS Web2.2.11
`
`0788
`
`0788
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`cat
`
`Application Data Sheet 37 CFR 1.76
` Title of Invention
`
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`generated within this form by selecting the Add button.
`
`
`
`US
`
`City|Newport Beach State/Province|CA Country of Residencé
`
`Mailing Addressof Inventor:
`
`Address 1
`
`Address 2
`
`4
`Inventor
`Legal Name
`
`aR
`
`() Active US Military Service
`esidence Information (Select One) @) US Residency © NonUS Residency
`StatelProvince
`Country of Residence
`
`Mailing Addressof Inventor:
`
`Address1
`
`Address 2
`
`869 Avenida Avenue
`
`All
`
`Inventors Must Be Listed - Additional
`
`Inventor
`
`Information blocks may be
`
`CorrespondenceInformation:
`
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`
`[_] An Addressis being provided for the correspondenceInformation of this application.
`
`Customer Number
`
`051957
`
`Email Address
`
`Patents_ip@Allergan.com
`
`Application Information:
`
`
`Filing By Reference:
`
`Title of the Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`Attorney Docket Number| 17618CONGCON(AP) Small Entity Status Claimed
`Application Type
`Nonprovisional
`
`)
`
`[_]
`
`Total Number of Drawing Sheets(if any) P| Suggested Figure for Publication (if any) |
`
`EFS Web 2.2.11
`
`0789
`
`0789
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`—
`
`
`
`Title of Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below(i.e., “Domestic Benefit/National Stage Information” and “Foreign Priority Information”).
`
`For the purposes ofa filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previouslyfiled application, subject to conditions and requirements of 37 CFR 1.57(a).
`
`i
`
`Application number of the previously
`filed application
`
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country
`
`Publication Information:
`
`[_] Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`Request Not to Publish. | hereby request that the attached application not be published under
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`
`publication at eighteen months after filing.
`051957
`
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below.
`If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`Please Select One: © US Patent Practitioner|CE) Limited Recognition (37 CFR 11.9)@ Customer Number
`
`Customer Number
`
`
`
`Domestic Benefit/National Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage
`entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required
`by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`Whenreferring to the current application, please leave the application numberblank.
`
`Filing Date (YYYY-MM-DD)
`Prior Application Number
`Application Number
`Continuity Type
`2013-08-07
`13961828
`Pe Continuation of
`Prior Application Status|Patented
`Application
`.
`Prior Application
`Filing Date
`Issue Date
`
`13961828
`
`Continuation of
`
`11897177
`
`2007-08-28
`
`8618064
`
`2013-12-31
`
`Prior Application Status|Abandoned
`
`EFS Web 2.2.11
`
`0790
`
`0790
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`cat
`
`Application Data Sheet 37 CFR 1.76
` Title of Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`)
`
`
`Application Number
`Continuity Type
`
`
`
`
`
`Prior Application Status
`
`10927857
`
`Claims benefit of provisional
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD
`
`
`
`2003-09-15
`
`
`
`
`
`
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(d). Whenpriority is claimed to a foreign application
`that is eligible for retrieval underthe priority document exchange program (PDX) the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(h)(1) and (2). Under the PDX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).
`
`Application Number
`
`Country!
`
`Filing Date (YYYY-MM-DD)
`
`Access Code(if applicable)
`
`Add button.
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effectivefiling date on or after March
`[] 16, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`Authorization to Permit Access:
`
`><] Authorization to Permit Accessto the Instant Application by the Participating Offices
`
`EFS Web 2.2.11
`
`0791
`
`0791
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`cat
`
`Title of Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`Application Data Sheet 37 CFR 1.76
`
`
`
`
`)If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO),
`
`the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO),
`and any other intellectual property offices in which a foreign application claiming priority to the instant patent application
`is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checkedif the applicant
`does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority
`to the instant patent application is filed to have accessto the instant patent application.
`
`In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect
`to: 1) the instant patent application-as-filed; 2) any foreign application to which the instant patent application
`claimspriority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of
`37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. application-as-filed from which benefit is
`sought in the instant patent application.
`
`In accordance with 37 CFR 1.14(c), access may be provided to information concerning the dateof filing this Authorization.
`
`
`
`
`
`
`Applicant Information:
`
`
`
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`1
`Applicant
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise showssufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom theinventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or morejoint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`© Legal Representative under 35 U.S.C. 117
`
`© Joint Inventor
`
`© Person to whom the inventor is obligatedto assign.
`
`© Person who showssufficient proprietary interest
`
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`Name of the Deceased or Legally Incapacitated Inventor:
`
`If the Applicant is an Organization check here.
`Organization Name
`Allergan, Inc.
`
`Xx
`
`Mailing AddressInformation For Applicant:
`
`Address1
`
`Address 2
`
`2525 Dupont Drive, T2-7H
`
`Phone Number
`
`(714) 246-6996
`
`Fax Number
`
`(714) 246-4249
`
`EFS Web 2.2.11
`
`0792
`
`
`
`
`
`
`0792
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`— Title of Invention
`
`Application Data Sheet 37 CFR 1.76
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`Email Address
`
`Patents_ip@Allergan.com
`
`
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`Assignee Information including Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not subsitute for compliance with any requirement of part 3 of Title 37 of CFR to
`have an assignment recorded by the Office.
`
`Assignee
`
`Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent
`application publication . An assignee-applicant identified in the “Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee-applicant, complete this section onlyif identification as an assignee is also desired on the
`patent application publication.
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`[|
`
`selecting the Add button.
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`Email Address
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`
`Signature:
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and
`certifications.
`
`Additional Signature may be generated within this form by selecting the Add button.
`
`EFS Web 2.2.11
`
`0793
`
`0793
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`— Title of Invention
`
`Application Data Sheet 37 CFR 1.76
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web2.2.11
`
`0794
`
`0794
`
`

`

`Privacy Act Statement
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552)
`and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine
`whether the Freedom of Information Act requires disclosure of these records.
`
`A record from this system of records maybe disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or
`administrative tribunal, including disclosures to opposing counselin the course of settlement negotiations.
`
`3.
`
`A record in this system of records maybedisclosed, as a routine use, to a Member of Congress submitting a request involving an
`individual, to whom the record pertains, whenthe individual has requested assistance from the Member with respect to the subject matter of
`the record.
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that:
`(1) the general authority for the collection
`of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is
`used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent.
`If you do not
`furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonmentof the application or expiration of the patent.
`
`USPTO becomesawareofa violation or potential violation of law or regulation.
`
`A record in this system of records maybe disclosed, as a routine use, to a contractor of the Agency having need for the information in
`order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed,
`as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent C 0 0 p eration Treaty.
`
`A record in this system of records maybedisclosed, as a routine use, to another federal agency for purposes of National Security
`review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee,
`during an inspection of records conducted by GSAaspart of that agency's responsibility to recommend improvementsin records
`managementpractices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the
`GSAregulations governing inspection of records for this purpose, and any otherrelevant (i.e., GSA or Commerce) directive. Such
`disclosure shall not be used to make determinations aboutindividuals.
`
`A record from this system of records maybe disclosed, as a routine use, to the public after either publication of the application pursuant
`to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, as a routine use, to the public if the record wasfiled in an application which became abandonedor in which the proceedings were
`terminated and which application is referenced by either a published application, an application open to public inspections or an issued
`patent.
`
`A record from this system of records maybe disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the
`
`EFS Web 2.2.11
`
`O79
`
`0795
`
`

`

`Docket No. 17618CON6CON] (AP}
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Applicant: Acheampong, ef al.
`
`| Examiner: TBA
`
`Serial No.; TBA
`
`Filed: Herewith
`
`For. METHODS OF PROVIDING
`THERAPEUTIC EFFECTS USING
`wenncnencenennonenenecnenenceneneneceneoncunanenannnecennanenennanononnaenuosmnnanncnennnnanenannnnenennsnenennsned!
`CYCLOSPORIN COMPONENTS
`
`Group Art Unit:TRA
`
`Confirmation No, TBA
`
`Customer No.: 51937
`
`PRELIVENARY AMENDMENT
`
`Commissioner for Patents
`P.O. Box 1456
`Alexandria,